Key clinical point: Age has a significant impact on the biology and outcomes of patients with acute myeloid leukemia (AML). The proportion of patients in the favorable-risk group receiving induction remission chemotherapy and rates of complete response (CR) among patients who received induction therapy decreased with age.
Major finding: Only 6% of patients older than 70 years were in the favorable-risk group, and less than 50% of patients older than 70 years received induction therapy. After induction therapy, 81.5% of patients with acute promyelocytic leukemia (APL) and 62.4% of non-APL patients achieved CR, which decreased with increasing age.
Study details: Findings are from a retrospective analysis of 3,011 adult patients with AML, of which 329 patients had APL and 2,682 were non-APL patients.
Disclosures: This study was supported by the Korean Society of Hematology AML/MDS Working Party and funding from Gachon University to H Kim. The authors declared no conflicts of interest.
Source: Yoo KH et al. PLoS One. 2021 May 7. doi: 10.1371/journal.pone.0251011 .